The group's principal activity is to develop and market breast cancer risk assessment tool. The group is a development stage company. It is involved with portfolio companies, which are involved in cancer therapy and neurodegenerative diagnostics. It also serves as a strategic advisor in key aspects of science, product commercialization, business issues and financial development by providing management expertise aimed at transforming promising medical technology into successful commercial products. The group has selected the areas of oncology and neurology as its primary sectors of interest, based on the perceived market potential for new treatments and diagnostics.
